Furthermore, whole-exome sequencing of pancreatic cancer indicated that in 75% of these cases, RBM10 mutations were associated with favorable patient prognoses, suggesting these mutations could improve the survival rate and prolong the survival period (6). Here, RBM10 is linked to familial pancreatic carcinoma.